Simon Farrell has filed 13 insider transactions across 1 company since February 2024.
Most recent transaction: a grant/award of 160000 shares of Trevi Therapeutics, Inc. ($TRVI) on February 19, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | A | Stock Option (right to buy) | 160000 | $0.00 | 160,000.0000 | 145,104,986 | 9999.99% | 0.11% |
| May 31, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | A | Performance Stock Option (right to buy) | 72000 | $0.00 | 110,400.0000 | 101,971,873 | 187.50% | 0.07% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Common Stock | 17500 | $3.21 | 63,150.0000 | 101,971,873 | 38.34% | 0.02% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Common Stock | 31250 | $0.51 | 158,213.0000 | 101,971,873 | 24.61% | 0.03% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | S | Common Stock | 76963 | $6.73 | 81,250.0000 | 101,971,873 | 48.65% | 0.08% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | S | Common Stock | 4350 | $7.15 | 76,900.0000 | 101,971,873 | 5.35% | 0.00% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | A | Performance Stock Option (right to buy) | 38400 | $0.00 | 38,400.0000 | 101,971,873 | 9999.99% | 0.04% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Performance Stock Option (right to buy) | 17500 | $0.00 | 0.0000 | 101,971,873 | 100.00% | 0.02% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Stock Option (right to buy) | 63813 | $0.00 | 11,187.0000 | 101,971,873 | 85.08% | 0.06% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Stock Option (right to buy) | 31250 | $0.00 | 18,750.0000 | 101,971,873 | 62.50% | 0.03% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | M | Common Stock | 63813 | $3.91 | 126,963.0000 | 101,971,873 | 101.05% | 0.06% |
| Feb. 18, 2025 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | A | Stock Option (right to buy) | 225500 | $0.00 | 225,500.0000 | 101,971,873 | 9999.99% | 0.22% |
| Feb. 15, 2024 | Trevi Therapeutics, Inc. | $TRVI | Simon Farrell | Chief Commercial Officer | A | Stock Option (right to buy) | 175000 | $0.00 | 175,000.0000 | 99,033,373 | 9999.99% | 0.18% |